Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
The aim of this prospective, multicenter, phase II study was to investigate the combination of pegylated liposomal doxorubicin (Caelyx) 40 mg/m2 on day 1 every 28 days, dexamethasone 40 mg p.o. on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma. Twenty-six percent of patients achieved a complete response, 6% a near complete response, 6% a very good partial response, 38% a partial response, 16% a minor response and 8% progressed, for an overall response rate of 92%. The median event-free survival was 17 months and the median overall survival was not reached. Grade 3 non-hematologic toxicity occurred in 12% of patients, thromboembolic disease in 12% and severe infection in 16%. The combination of pegylated liposomal doxorubicin, dexamethasone an thalidomide is safe and very effective in advanced multiple myeloma.
Offidani
Massimo
M
Clinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche. m.offidani@ao-umbertoprimo.marche.it
Corvatta
Laura
L
Marconi
Monica
M
Visani
Giuseppe
G
Alesiani
Francesco
F
Brunori
Marino
M
Galieni
Piero
P
Catarini
Massimo
M
Burattini
Maurizio
M
Centurioni
Riccardo
R
Rupoli
Serena
S
Scortechini
Anna Rita
AR
Giuliodori
Luciano
L
Candela
Marco
M
Capelli
Debora
D
Montanari
Mauro
M
Olivieri
Attilio
A
Piersantelli
Maria-Novella
MN
Leoni
Pietro
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D011092:Polyethylene Glycols; D016879:Salvage Therapy / Q000379:methods; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage
D011092:Polyethylene Glycols; D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin